Table 1 Characteristics of patients
|  | ExRT (n = 72) | RP (n = 48) | p |
|---|---|---|---|
Age (years) | 67.7 ± 6.6 67.2 (43.9–80.1) | 64.5 ± 7.6 65.3 (47.3–79.9) | 0.017 |
Follow-up (months) | 60.2 ± 30.3 53.7 (10.3–125.8) | 41.3 ± 21.5 37.8 (9.6–128.9) | < 0.001 |
Pretreatment PSA (ng/mL) | 34.6 ± 30.7 25.4 (3.4–172) | 27.2 ± 26.3 17 (3.2–138.7) | 0.049 |
Pretreatment PSA ≥20 ng/mL n (%) | 50 (69.4) | 23 (47.9) | 0.022 |
Clinical T stage n (%) | |||
 T2 | 46 (63.9) | 35 (72.9) | 0.474 |
 T3 | 22 (30.6) | 12 (25.0) | |
 T4 | 4 (5.6) | 1 (2.1) | |
Gleason score (biopsy) n (%) | |||
 6 | 17 (23.6) | 8 (16.7) | 0.636 |
 7 | 15 (20.8) | 10 (20.8) | |
  > 8 | 40 (55.6) | 30 (62.5) | |